Vaxart, Inc. SEC filings VXRT
Vaxart, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to May 18, 2011. Its latest annual report, Form ARS, was filed on Jun 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 4 | Insider transaction | Oct 20, 2026 | Oct 16, 2026 |
| 3 | Initial insider ownership | Oct 20, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 19, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Other events
|
Aug 25, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Other events
|
Jul 28, 2026 | Jul 27, 2026 |
| 4 | Insider transaction | Jul 20, 2026 | Jul 16, 2026 |
| 4 | Insider transaction | Jul 17, 2026 | Jul 16, 2026 |
| 4 | Insider transaction | Jul 17, 2026 | Jul 16, 2026 |
| 4 | Insider transaction | Jul 17, 2026 | Jul 16, 2026 |
| 4 | Insider transaction | Jul 17, 2026 | Jul 16, 2026 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Jul 17, 2026 | Jul 16, 2026 |
| 8-K |
Current report
Other events
|
Jul 7, 2026 | Jul 6, 2026 |
| DEFA14A | Additional proxy material | Jul 6, 2026 | — |
| DEFA14A | Additional proxy material | Jul 2, 2026 | — |
| DFAN14A | Filing | Jul 2, 2026 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 2, 2026 | Jul 1, 2026 |
| DEFA14A | Additional proxy material | Jul 1, 2026 | — |
| DEFA14A | Additional proxy material | Jun 26, 2026 | — |
| DEFA14A | Additional proxy material | Jun 26, 2026 | — |
| 8-K |
Current report
Material agreement, Other events
|
Jun 26, 2026 | Jun 22, 2026 |
| DEFA14A | Additional proxy material | Jun 26, 2026 | — |
| DEFA14A | Additional proxy material | Jun 26, 2026 | — |
| DFAN14A | Filing | Jun 22, 2026 | — |
| DEFA14A | Additional proxy material | Jun 16, 2026 | — |
| DEFA14A | Additional proxy material | Jun 16, 2026 | — |
| DFAN14A | Filing | Jun 9, 2026 | — |
| DEFA14A | Additional proxy material | Jun 8, 2026 | — |
| DFAN14A | Filing | Jun 8, 2026 | — |
| DEFA14A | Additional proxy material | Jun 8, 2026 | — |
| DEFC14A | Filing | Jun 4, 2026 | — |
| DEFA14A | Additional proxy material | Jun 1, 2026 | — |
| ARS | Annual report to shareholders | Jun 1, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Jun 1, 2026 | — |
| DEFA14A | Additional proxy material | Jun 1, 2026 | — |
| DEFC14A | Proxy statement | Jun 1, 2026 | — |
| PRER14A | Proxy statement | May 29, 2026 | — |
| PRRN14A | Filing | May 29, 2026 | — |
| 4 | Insider transaction | May 26, 2026 | May 22, 2026 |
| PREC14A | Filing | May 21, 2026 | — |
| 4 | Insider transaction | May 21, 2026 | May 19, 2026 |
| DEFA14A | Additional proxy material | May 20, 2026 | — |
| DEFA14A | Additional proxy material | May 20, 2026 | — |
| PREC14A | Proxy statement | May 19, 2026 | — |
| DEFA14A | Additional proxy material | May 19, 2026 | — |
| 8-K |
Current report
Other events
|
May 19, 2026 | May 19, 2026 |
| DEFA14A | Additional proxy material | May 19, 2026 | — |
| 424B3 | Prospectus | May 19, 2026 | — |
| EFFECT | Filing | May 18, 2026 | — |
| S-1/A | Amended registration statement | May 18, 2026 | — |
| S-1 | Registration statement | May 8, 2026 | — |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 424B5 | Prospectus supplement | May 4, 2026 | — |
| 4 | Insider transaction | May 1, 2026 | Apr 23, 2026 |
| 3 | Initial insider ownership | May 1, 2026 | Apr 23, 2026 |
| EFFECT | Filing | Apr 30, 2026 | — |
| 10-K/A | Amended annual report | Apr 30, 2026 | Dec 31, 2025 |
| CORRESP | Letter to the SEC | Apr 29, 2026 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 23, 2026 | Apr 23, 2026 |
| UPLOAD | Letter from the SEC | Apr 21, 2026 | — |
| 8-K |
Current report
Other events
|
Apr 21, 2026 | Apr 20, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Apr 17, 2026 | Apr 16, 2026 |
| S-3 | Shelf registration | Apr 16, 2026 | — |
| 4 | Insider transaction | Mar 31, 2026 | Mar 28, 2026 |
| 4 | Insider transaction | Mar 31, 2026 | Mar 28, 2026 |
| 4 | Insider transaction | Mar 26, 2026 | Mar 24, 2026 |
| 4 | Insider transaction | Mar 26, 2026 | Mar 24, 2026 |
| 4 | Insider transaction | Mar 26, 2026 | Mar 24, 2026 |
| 4 | Insider transaction | Mar 26, 2026 | Mar 24, 2026 |
| 4 | Insider transaction | Mar 20, 2026 | Mar 18, 2026 |
| 4 | Insider transaction | Mar 20, 2026 | Mar 18, 2026 |
| 4 | Insider transaction | Mar 20, 2026 | Mar 18, 2026 |
| 4 | Insider transaction | Mar 20, 2026 | Mar 18, 2026 |
| 4 | Insider transaction | Mar 18, 2026 | Mar 16, 2026 |
| 4 | Insider transaction | Mar 18, 2026 | Mar 16, 2026 |
| 4 | Insider transaction | Mar 18, 2026 | Mar 16, 2026 |
| 4 | Insider transaction | Mar 18, 2026 | Mar 16, 2026 |
| 4 | Insider transaction | Mar 18, 2026 | Mar 16, 2026 |
| 10-K | Annual report | Mar 13, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 12, 2026 | Mar 12, 2026 |
| 4 | Insider transaction | Feb 5, 2026 | Feb 2, 2026 |
| 4 | Insider transaction | Feb 5, 2026 | Feb 2, 2026 |
| 4 | Insider transaction | Feb 5, 2026 | Feb 2, 2026 |
| 8-K |
Current report
Agreement ended
|
Dec 29, 2025 | Dec 18, 2025 |
| 4 | Insider transaction | Dec 8, 2025 | Dec 4, 2025 |
| 144 | Notice of proposed sale | Dec 8, 2025 | — |
| 4 | Insider transaction | Dec 5, 2025 | Nov 17, 2025 |
| 25-NSE | Delisting notice | Nov 21, 2025 | — |
| 4 | Insider transaction | Nov 21, 2025 | Nov 17, 2025 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2025 | Nov 13, 2025 |
| 424B5 | Prospectus supplement | Nov 5, 2025 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Nov 5, 2025 | Nov 4, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 10, 2025 | Oct 8, 2025 |
| 8-K |
Current report
Listing notice
|
Sep 19, 2025 | Sep 19, 2025 |
| 8-K |
Current report
Other events
|
Sep 19, 2025 | Sep 18, 2025 |
| PX14A6G | Filing | Sep 18, 2025 | — |
| PX14A6G | Filing | Sep 10, 2025 | — |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Sep 8, 2025 | Sep 5, 2025 |
| DEFA14A | Additional proxy material | Sep 8, 2025 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 2, 2025 | Sep 2, 2025 |
| PX14A6G | Filing | Sep 2, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 29, 2025 | Aug 27, 2025 |
| DEFA14A | Additional proxy material | Aug 21, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 21, 2025 | Aug 20, 2025 |
| 4 | Insider transaction | Aug 19, 2025 | Jul 17, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 15, 2025 | Aug 14, 2025 |
| DEFA14A | Additional proxy material | Aug 15, 2025 | — |
| 10-Q | Quarterly report | Aug 13, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2025 | Aug 13, 2025 |
| DEFA14A | Additional proxy material | Aug 8, 2025 | — |
| DEF 14A | Proxy statement | Aug 6, 2025 | Sep 5, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Aug 6, 2025 | Aug 5, 2025 |
| 4 | Insider transaction | Jul 31, 2025 | Jul 29, 2025 |
| PRE 14A | Preliminary proxy statement | Jul 24, 2025 | Sep 5, 2025 |
| 8-K |
Current report
Other events
|
Jul 8, 2025 | Jul 8, 2025 |
| 8-K |
Current report
Listing notice
|
Jul 2, 2025 | Jul 1, 2025 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Jun 17, 2025 | Jun 13, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 13, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 13, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 13, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 13, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 13, 2025 |
| 8-K |
Current report
Other events
|
Jun 11, 2025 | Jun 11, 2025 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Jun 2, 2025 | Jun 2, 2025 |
| DEFA14A | Additional proxy material | May 29, 2025 | — |
| PRE 14A | Preliminary proxy statement | May 29, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
May 28, 2025 | May 28, 2025 |
| DEFA14A | Additional proxy material | May 28, 2025 | — |
| 8-K |
Current report
Other events
|
May 28, 2025 | May 27, 2025 |
| 144 | Notice of proposed sale | May 27, 2025 | — |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
May 22, 2025 | May 21, 2025 |
| 4 | Insider transaction | May 20, 2025 | May 19, 2025 |
| 3 | Initial insider ownership | May 20, 2025 | May 19, 2025 |
| 4 | Insider transaction | May 19, 2025 | May 19, 2025 |
| DEFA14A | Additional proxy material | May 16, 2025 | — |
| 8-K |
Current report
Other events
|
May 16, 2025 | May 16, 2025 |
| DEFA14A | Additional proxy material | May 16, 2025 | — |
| 8-K |
Current report
Other events
|
May 15, 2025 | May 15, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
May 13, 2025 | May 12, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 13, 2025 | May 13, 2025 |
| DEFA14A | Additional proxy material | May 12, 2025 | — |
| 8-K |
Current report
Other events
|
May 12, 2025 | May 12, 2025 |
| DEFA14A | Additional proxy material | May 5, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
May 5, 2025 | May 5, 2025 |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| 8-K |
Current report
Material agreement, Other events
|
Apr 28, 2025 | Apr 24, 2025 |
| ARS | Annual report to shareholders | Apr 10, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 10, 2025 | — |
| DEF 14A | Proxy statement | Apr 10, 2025 | May 21, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 8, 2025 | — |
| 4 | Insider transaction | Apr 1, 2025 | Mar 28, 2025 |
| 4 | Insider transaction | Apr 1, 2025 | Mar 28, 2025 |
| PRE 14A | Preliminary proxy statement | Mar 31, 2025 | May 21, 2025 |
| 4 | Insider transaction | Mar 26, 2025 | Mar 24, 2025 |
| 4 | Insider transaction | Mar 26, 2025 | Mar 24, 2025 |
| 4 | Insider transaction | Mar 26, 2025 | Mar 24, 2025 |
| 4 | Insider transaction | Mar 26, 2025 | Mar 24, 2025 |
| 4 | Insider transaction | Mar 26, 2025 | Mar 24, 2025 |
| 8-K |
Current report
Material agreement
|
Mar 21, 2025 | Mar 21, 2025 |
| 424B5 | Prospectus supplement | Mar 21, 2025 | — |
| 8-K |
Current report
Results of operations
|
Mar 21, 2025 | Mar 20, 2025 |
| 4 | Insider transaction | Mar 20, 2025 | Mar 18, 2025 |
| 4 | Insider transaction | Mar 20, 2025 | Mar 28, 2023 |
| 4 | Insider transaction | Mar 20, 2025 | Mar 18, 2025 |
| 4 | Insider transaction | Mar 20, 2025 | Mar 18, 2025 |
| 4 | Insider transaction | Mar 20, 2025 | Mar 18, 2025 |
| 10-K | Annual report | Mar 20, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Other events
|
Mar 11, 2025 | Mar 11, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Feb 24, 2025 | Feb 21, 2025 |
| 8-K |
Current report
Material agreement
|
Feb 10, 2025 | Feb 7, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 10, 2025 | — |
| 4 | Insider transaction | Feb 4, 2025 | Feb 2, 2025 |
| 4 | Insider transaction | Feb 4, 2025 | Feb 2, 2025 |
| 4 | Insider transaction | Feb 4, 2025 | Feb 2, 2025 |
| 4 | Insider transaction | Jan 29, 2025 | Jan 28, 2025 |
| 3 | Initial insider ownership | Jan 29, 2025 | Jan 28, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 28, 2025 | Jan 24, 2025 |
| 8-K |
Current report
Other events
|
Jan 21, 2025 | Jan 13, 2025 |
| 8-K |
Current report
Listing notice
|
Dec 31, 2024 | Dec 31, 2024 |
| 8-K |
Current report
Material agreement
|
Dec 27, 2024 | Dec 20, 2024 |
| 4 | Insider transaction | Dec 17, 2024 | Dec 15, 2024 |
| 8-K |
Current report
Other events
|
Dec 5, 2024 | Dec 2, 2024 |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 424B5 | Prospectus supplement | Oct 8, 2024 | — |
| 8-K |
Current report
Agreement ended
|
Oct 8, 2024 | Oct 8, 2024 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 30, 2024 | Sep 27, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Listing notice
|
Jul 5, 2024 | Jul 2, 2024 |
| S-8 | Employee stock plan registration | Jul 3, 2024 | — |
| 8-K/A |
Amended current report
Shareholder vote results
|
Jun 20, 2024 | Jun 11, 2024 |
| 4 | Insider transaction | Jun 20, 2024 | Jun 18, 2024 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VXRT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 72444
- Former names
- Aviragen Therapeutics, Inc. (until Feb 15, 2018); Biota Pharmaceuticals, Inc. (until Apr 13, 2016); NABI BIOPHARMACEUTICALS (until Nov 8, 2012); NABI BIOPHARMACEUTICALS (until Jun 29, 2010); NABI /DE/ (until Feb 14, 2002)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.